ArticleFrontiers in immunology2025
Preoperative TACE with PD-1 inhibitors and TKIs in beyond "up-to-seven" hepatocellular carcinoma: a propensity score matched analysis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HCC patients beyond the "up-to-seven" criteria face a high risk of recurrence, and optimal perioperative strategies warrant further investigation. This study evaluated the efficacy and safety of neoadjuvant TACE combined with PD-1 inhibitors and TKIs in this population. Methods: We retrospectively analyzed 126 HCC patients who underwent curative liver resection between January 2021 and June 2024. Of these, 73 patients received preoperative TACE with PD-1 inhibitors and TKIs (PST group), and 53 underwent direct surgery without preoperative therapy (Surgery group). PSM was applied to control for confounding factors, resulting in 39 matched pairs. The primary endpoints were RFS and OS, with secondary endpoints including intraoperative blood loss, surgical time, and complications. Results: After matching, the PST group demonstrated significantly superior RFS and OS compared to the Surgery group (P < 0.05). The median RFS was 26 months in the PST group versus 13 months in the Surgery group (P = 0.029). There were no significant differences in postoperative complications between the two groups (P = 0.365). The PST group exhibited longer surgical times (P < 0.001) and slightly higher intraoperative blood loss, suggesting increased surgical complexity due to preoperative therapy. Treatment-related adverse events were predominantly grade 1-2, with few grade 3-4 events. Conclusion: Preoperative TACE with PD-1 inhibitors and TKIs was associated with improved survival without increasing severe complications in beyond "up-to-seven" HCC, suggesting a promising perioperative strategy for high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.